Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 1
2002 1
2006 2
2008 1
2010 1
2012 1
2015 1
2018 1
2019 1
2020 2
2021 1
2022 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Endometrial Carcinoma"
Page 1
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Marabelle A, et al. Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10. Lancet Oncol. 2020. PMID: 32919526 Clinical Trial.
Eligible patients were aged 18 years or older, had a histologically or cytologically confirmed advanced (ie, unresectable or metastatic, or both) incurable solid tumour (eligible tumour types were anal, biliary, cervical, endometrial, mesothelioma, neuroendocrine, s …
Eligible patients were aged 18 years or older, had a histologically or cytologically confirmed advanced (ie, unresectable or metastat …
Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
Lee L, Matulonis U. Lee L, et al. Gynecol Oncol. 2019 Jul;154(1):236-245. doi: 10.1016/j.ygyno.2019.03.255. Epub 2019 Apr 14. Gynecol Oncol. 2019. PMID: 30995960 Review.
Gynecologic cancers are attractive targets for immune checkpoint blockade, and IO agents may be used in combination with definitive chemoradiotherapy to enhance radiosensitivity and thus local control for unresected disease as well as control distant micrometastatic spread …
Gynecologic cancers are attractive targets for immune checkpoint blockade, and IO agents may be used in combination with definitive chemorad …
Immunohistochemical Expression of Programmed Death Ligand 1(PDL1) in Endometrial Carcinoma and Its Relation to CD4 and CD8 Positive Immune Cells.
Salama ME, Khairy DA. Salama ME, et al. Asian Pac J Cancer Prev. 2022 Jul 1;23(7):2491-2496. doi: 10.31557/APJCP.2022.23.7.2491. Asian Pac J Cancer Prev. 2022. PMID: 35901358 Free PMC article.
OBJECTIVES: Endometrial cancer (EC) is the most common cancer of the female genital tract. ...CD4 and CD8 were expressed in 79% of cases. Statistically significant correlations were observed between PDL1 expression and patients mean age, LVSI, TILS score and …
OBJECTIVES: Endometrial cancer (EC) is the most common cancer of the female genital tract. ...CD4 and CD8 were expressed in 79% of ca …
Second-line lenvatinib in patients with recurrent endometrial cancer.
Vergote I, Powell MA, Teneriello MG, Miller DS, Garcia AA, Mikheeva ON, Bidzinski M, Cebotaru CL, Dutcus CE, Ren M, Kadowaki T, Funahashi Y, Penson RT. Vergote I, et al. Gynecol Oncol. 2020 Mar;156(3):575-582. doi: 10.1016/j.ygyno.2019.12.039. Epub 2020 Jan 17. Gynecol Oncol. 2020. PMID: 31955859 Free article. Clinical Trial.
OBJECTIVE: This study assessed the efficacy of lenvatinib, a multitargeted tyrosine kinase inhibitor, as second-line therapy in patients with unresectable endometrial cancer. The primary end point was the objective response rate (ORR) as assessed by independent radi …
OBJECTIVE: This study assessed the efficacy of lenvatinib, a multitargeted tyrosine kinase inhibitor, as second-line therapy in patients wit …
Aromatase inhibitor therapy for endometrial stromal sarcoma - two-centre experience.
Serkies K, Abacjew-Chmyłko A, Wieczorek-Rutkowska M, Pęksa R. Serkies K, et al. Ginekol Pol. 2018;89(11):607-610. doi: 10.5603/GP.a2018.0104. Ginekol Pol. 2018. PMID: 30508212 Free article.
OBJECTIVES: Endocrine therapy is the recommended systemic treatment for steroid receptor positive endometrial stromal sarcoma (ESS). There is no current consensus on the optimal hormonal therapy for ESS. ...RESULTS: Disease stabilization was achieved in four cases (80%), i …
OBJECTIVES: Endocrine therapy is the recommended systemic treatment for steroid receptor positive endometrial stromal sarcoma (ESS). …
Primary extrauterine endometrial stromal neoplasms: a clinicopathologic study of 20 cases and a review of the literature.
Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Hendrickson MR. Chang KL, et al. Int J Gynecol Pathol. 1993 Oct;12(4):282-96. Int J Gynecol Pathol. 1993. PMID: 8253545 Review.
The other four patients who were treated after a relapse showed no evidence of disease after relapse at 36, 57, 63, and 146 months, respectively. Two of the 13 patients had tumor considered unresectable at the time of diagnosis; both died of disease at 5 and 10 months, res …
The other four patients who were treated after a relapse showed no evidence of disease after relapse at 36, 57, 63, and 146 months, respecti …
Endometrial stromal sarcoma arising from endometriosis: a clinicopathological study and literature review.
Lan C, Huang X, Lin S, Cai M, Liu J. Lan C, et al. Gynecol Obstet Invest. 2012;74(4):288-97. doi: 10.1159/000341706. Epub 2012 Sep 19. Gynecol Obstet Invest. 2012. PMID: 22986788 Free article. Review.
OBJECTIVES: We aimed to investigate the nature of endometrial stromal sarcoma (ESS) arising from endometriosis. METHODS: The clinical data of 5 patients with ESS arising from endometriosis were reviewed retrospectively. ...The expression of EGFR and VEGF was observed …
OBJECTIVES: We aimed to investigate the nature of endometrial stromal sarcoma (ESS) arising from endometriosis. METHODS: The clinical …
Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.
Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Grunberg SM, et al. Cancer Invest. 2006 Dec;24(8):727-33. doi: 10.1080/07357900601062339. Cancer Invest. 2006. PMID: 17162554 Clinical Trial.
Serial follow-up allowed evaluation for tolerability and side effects of long-term therapy as well as observation for efficacy (tumor shrinkage or improvement in visual fields). ...CONCLUSIONS: Long-term administration of mifepristone is feasible and clinically well tolera …
Serial follow-up allowed evaluation for tolerability and side effects of long-term therapy as well as observation for efficacy (tumor …
Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer.
Ushijima K, Ota S, Komai K, Matsuo G, Motoshima S, Honda S, Tomonari R, Sugiyama T, Kamura T. Ushijima K, et al. Int Surg. 2002 Jul-Sep;87(3):185-90. Int Surg. 2002. PMID: 12403096
Sixty-five patients with unresectable advanced epithelial ovarian cancer who underwent exploratory laparotomy or unilateral oophorectomy were reviewed. ...NAC and IRS offered patients with unresectable tumors survival similar to that of those with suboptimally resec …
Sixty-five patients with unresectable advanced epithelial ovarian cancer who underwent exploratory laparotomy or unilateral oophorect …
Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors.
Akagi K, Oki E, Taniguchi H, Nakatani K, Aoki D, Kuwata T, Yoshino T. Akagi K, et al. Cancer Sci. 2021 Mar;112(3):1105-1113. doi: 10.1111/cas.14798. Epub 2021 Feb 7. Cancer Sci. 2021. PMID: 33403729 Free PMC article.
Microsatellite instability-high (MSI-H) is an important biomarker for predicting the effect of immune checkpoint inhibitors (ICIs) on advanced solid tumors. ...Microsatellite instability-high was detected in 30 cancer types. Common cancer types were: endometrial can …
Microsatellite instability-high (MSI-H) is an important biomarker for predicting the effect of immune checkpoint inhibitors (ICIs) on …
17 results